ISSN: 2149-2247 | E-ISSN: 2149-2549
Volume : 44 Issue : 3 Year : 2022
Immunotherapies for Myelodysplastic Syndromes: Current State and Future Developments [Erciyes Med J]
Erciyes Med J. 2022; 44(3): 245-251 | DOI: 10.14744/etd.2021.39205

Immunotherapies for Myelodysplastic Syndromes: Current State and Future Developments

Nikolaos Papadantonakis1, George Deeb2
1Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Emory University Hospital, Atlanta, GA, USA
2Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA

Myelodysplastic syndromes (MDS) encompass a heterogeneous set of myeloid neoplasms characterized by ineffective hema-topoiesis. Treatment remains challenging, especially for patients with unfavorable disease features. Hypomethylating agents have remained the standard of care for higher-risk MDS for almost 2 decades. A plethora of clinical trials utilizing different approaches ranging from small molecule inhibitors to antibodies are underway. In this mini review, we describe recent developments in treatment approaches that incorporate antibodies in the therapeutic context of MDS apart from immune checkpoint inhibitors.

Keywords: Antibody, immunotherapy, MDS, myelodysplastic, treatment.

Nikolaos Papadantonakis, George Deeb. Immunotherapies for Myelodysplastic Syndromes: Current State and Future Developments. Erciyes Med J. 2022; 44(3): 245-251

Corresponding Author: Nikolaos Papadantonakis, United States of America
Manuscript Language: English
LookUs & Online Makale